The North America Gastrointestinal Therapeutics Market would witness market growth of 2.6% CAGR during the forecast period (2022-2028).
In many ways, the intestinal milieu represents a microcosm of the whole body. It possesses its intrinsic endocrine and nervous system, its barrier both to internal and external environments of the body, and its own intrinsic mucosal immune system, namely the so-called gut-associated lymphoid tissue (GALT).
Each of these enteric systems can account for pathophysiology and contribute to digestive disorders' clinical picture. Thus, therapeutic intervention for the disease of the GI tract is particularly demanding and should be strategically targeted, with the potential for drug side effects representing considerable accountability.
Gastrointestinal (GI) disease may affect one or more gastrointestinal tract regions, including the esophagus, small & large intestine, stomach, or accessory organs such as the pancreas, gallbladder, and liver. This disease class includes both structural and functional disorders. In addition, GI disorders may arise from diverse etiologies, including pathogens exposure, certain medications, stress, diet, abnormal cell growth, and more.
To foster safe usage of the over-the-counter (OTC) anti-diarrhea drug loperamide, the U.S. Food and Drug Administration (FDA) is collaborating with manufacturers to use blister packs or other single-dose packaging and to limit the number of doses in a package. Loperamide is an FDA-approved medication used to control diarrhea symptoms, including Travelers’ diarrhea.
The US market dominated the North America Gastrointestinal Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $11,546.6 million by 2028. The Canada market is poised to grow at a CAGR of 4.9% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 4% during (2022 - 2028).
Based on Type, the market is segmented into Branded and Generics. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on Route of Administration, the market is segmented into Injectable and Oral & Others. Based on Application, the market is segmented into Crohn's Disease, Ulcerative Colitis, GERD, IBS and Others. Based on Drug Class, the market is segmented into Biologics/Biosimilar, Anti-Diarrheal, Anti-Emetics, Digestive Enzymes, Aminosalicylates, Proton Pump Inhibitors, Laxatives & H2 Antagonists and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Gastrointestinal Therapeutics Market is Predict to reach $45.9 Billion by 2028, at a CAGR of 3.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, AbbVie, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc., Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.), Johnson & Johnson (Janssen Global Services, LLC), AstraZeneca PLC, Bayer AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.
By Type
By Distribution Channel
By Route of Administration
By Application
By Drug Class
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
